Kyntra Bio, Inc.
KYNB
$7.91
-$0.13-1.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.62M | 7.44M | 6.44M | 8.30M | 7.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.62M | 7.44M | 6.44M | 8.30M | 7.35M |
| Cost of Revenue | 27.19M | 26.32M | 24.07M | 38.65M | 57.40M |
| Gross Profit | -22.58M | -18.88M | -17.63M | -30.35M | -50.05M |
| SG&A Expenses | 27.67M | 25.46M | 27.71M | 28.80M | 32.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.87M | 51.78M | 51.78M | 67.45M | 90.27M |
| Operating Income | -50.25M | -44.34M | -45.34M | -59.16M | -82.92M |
| Income Before Tax | -30.92M | -56.66M | -58.30M | -52.35M | -87.49M |
| Income Tax Expenses | -1.00K | -92.00K | -90.00K | -88.00K | -85.00K |
| Earnings from Continuing Operations | -30.91 | -56.57 | -58.21 | -52.26 | -87.41 |
| Earnings from Discontinued Operations | 214.11M | 220.19M | 241.66M | 267.91M | 85.34M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 183.19M | 163.62M | 183.45M | 215.65M | -2.07M |
| EBIT | -50.25M | -44.34M | -45.34M | -59.16M | -82.92M |
| EBITDA | -50.04M | -43.92M | -44.59M | -58.06M | -81.29M |
| EPS Basic | 45.30 | 40.46 | 45.37 | 53.34 | -0.52 |
| Normalized Basic EPS | -8.53 | -7.67 | -7.91 | -10.13 | -13.74 |
| EPS Diluted | 45.30 | 40.46 | 45.37 | 53.34 | -0.52 |
| Normalized Diluted EPS | -8.53 | -7.67 | -7.91 | -10.13 | -13.74 |
| Average Basic Shares Outstanding | 16.19M | 16.18M | 16.17M | 16.16M | 16.13M |
| Average Diluted Shares Outstanding | 16.19M | 16.18M | 16.17M | 16.16M | 16.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |